Best selling report

Personalized Medicine Partnering Terms and Agreements

The Personalized Medicine Partnering Terms & Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies..... More

Featured partnering deals

Novartis signs multi-billion dollar pharma deal with GSK and Eli Lilly

April 22, 2014 : animal health, asset purchase, Eli Lilly, GSK, Novartis, oncology, vaccines

Novartis signs pharma deal with GlaxoSmithKline and Eli Lilly for exchange of oncology, vaccine and animal health business units.  more »

Actavis signs a pharma deal to acquire topical products from Akorn

April 22, 2014 : Actavis, asset purchase, big pharma, pharma partnering

Actavis has entered into pharma deal agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration. more »

 More partnering deals


Featured M&A deals

Big pharma, Valeant bids for a merger with Allergan

April 23, 2014 : Allergan, m& A, merger, Valeant

Big Pharma, Valeant Pharmaceuticals International Team Up To Make $45.6 Billion Allergan Bid. more »

Fosun Pharma enters into a m&a for Chindex

April 22, 2014 : acquisition, M&A

Fosun Pharmaceuticals and TPG Capital have agreed to enter into a m&a deal to acquire Chindex International for $461 million. more »

 More M&A deals

Featured financing deals

Guardant Health receives series B financing

April 23, 2014 : financing, financings

Guardant Health raises $60 million in series B financing. more »

Principia Biopharma gets $50 million in series B financing

April 23, 2014 : biotech, financing, financings

Principia Biopharma has secured a $50 million Series B private financing round. more »

 More financing deals

Latest Dealtalk

Rumours swirl of Pfizer bid for AstraZeneca triggering M&A fever

April 22, 2014 : AstraZeneca, big pharma, dealtalk, GlaxoSmithKline, joint venture, Novartis, Pfizer

The recently disclosed failed bid by Pfizer to acquire bigpharma rival AstraZeneca has analysts predicting several outcomes as M&A fever sweeps the pharma sector more »

Meda rejects Mylan M&A approach

April 7, 2014 : dealtalk, M&A

Swedish generic drugmaker Meda AB rejected a M&A approach by U.S. rival Mylan Inc to create a combined company worth around $24 billion. more »

 More dealtalk

Featured reports

Companion Diagnostics Partnering Terms and Agreements

Publication date: April 2014

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Biomarker Partnering Terms and Agreements

Publication date: April 2014

Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Publication date: April 2014

Orphan Diseases Partnering Terms and Agreements

Publication date: April 2014

Partnering Deals and Alliances with Big Pharma

Publication date: March 2014

Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Publication date: March 2014

 

NEW: Therapy deal reports covering all major indications

Including partnering in oncology, cardiovascular, CNS, metabolic, dermatology, dental, infectives, immunologypsychiatry, genitourinary.....plus many others

View all reports

Scorecard

Current Partnering provides access to key deal metrics for all leading partnering, M&A and financings - plus big pharma partnering activity and R&D spend metrics.

Available scorecards:

Partnering

M&A

Financing

Top 50 pharma partnering

Top 50 biotech partnering

Top pharma R&D spend

Deal metrics - by stage of development, therapy area, industry sector

Print Friendly
bannerpng
RSS Feed Linked In Twitter

Latest Tweets

cp300x1502gif
biotechnology-2014header300x150pxjpg
biovision-300-x-150gif